Skip to main content

Dr. Tiffany A. Traina, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
27
In the NPI registry since
2006
Medicare patients seen, 2024
115

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1999Medical school: Js Weill Medical College, Cornell University
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NY license 219019

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
115
Services billed
286
Patients’ average age
74
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes220106
New patient office or other outpatient visit, 60-74 minutes3535
Established patient office or other outpatient visit, 40-54 minutes1615

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Anastrozole
Other prescribers in New York, NY
57
Exemestane12
Tamoxifen Citrate
Other prescribers in New York, NY
12
Ibrance (palbociclib)11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 42 payments worth $75,011 in total to this clinician.

By company
AstraZeneca Pharmaceuticals LP$18,190
BioNTech SE$13,500
Gilead Sciences, Inc.$13,368
AstraZeneca UK Limited$9,295
Genentech, Inc.$7,333
Stemline Therapeutics Inc.$6,717
Corcept Therapeutics$4,049
Merck Sharp & Dohme LLC$2,560
By type
Consulting Fee$70,143
Compensation for services other than consulting (speaking, faculty)$4,000
Travel and Lodging$653
Food and Beverage$216

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 8, 2025BioNTech SE
Oct 8, 2025
Consulting Fee$6,750
Dec 12, 2025AstraZeneca UK Limited
Dec 12, 2025
Consulting Fee
DATROWAY · Oncology
Company’s descriptionResearch Related Service
$6,150
Oct 8, 2025BioNTech SE
Oct 8, 2025
Consulting Fee$4,725
Oct 9, 2025Stemline Therapeutics Inc.
Oct 9, 2025
Consulting Fee
Orserdu · Oncology
$4,680
May 2, 2025AstraZeneca Pharmaceuticals LP
May 2, 2025
Consulting Fee
DATROWAY · Oncology
Company’s descriptionResearch Related Service
$4,110
Dec 24, 2025Corcept Therapeutics
Dec 24, 2025
Compensation for services other than consulting (speaking, faculty)$4,000
Nov 11, 2025AstraZeneca Pharmaceuticals LP
Nov 11, 2025
Consulting Fee
DATROWAY · Oncology
$3,690
Sep 25, 2025AstraZeneca Pharmaceuticals LP
Sep 25, 2025
Consulting Fee
ENHERTU · Oncology
$3,280
Nov 13, 2025AstraZeneca Pharmaceuticals LP
Nov 13, 2025
Consulting Fee
DATROWAY · Oncology
$3,280
Dec 19, 2025Gilead Sciences, Inc.
Dec 19, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4238620;SAP;11024743
$3,050
All 37 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 24, 2025Corcept Therapeutics
Dec 24, 2025
Compensation for services other than consulting (speaking, faculty)$4,000
Dec 19, 2025Gilead Sciences, Inc.
Dec 19, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4238620;SAP;11024743
$3,050
Dec 16, 2025AstraZeneca Pharmaceuticals LP
Dec 16, 2025
Consulting Fee
ENHERTU · Oncology
Company’s descriptionResearch Related Service
$1,640
Dec 12, 2025AstraZeneca UK Limited
Dec 12, 2025
Consulting Fee
DATROWAY · Oncology
Company’s descriptionResearch Related Service
$6,150
Nov 30, 2025Gilead Sciences, Inc.
Nov 30, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4289909;GTF;11024743
$725
Nov 24, 2025Gilead Sciences, Inc.
Nov 24, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4252169;GTF;11024743
$725
Nov 20, 2025BioNTech SE
Nov 20, 2025
Consulting Fee$2,025
Nov 13, 2025AstraZeneca Pharmaceuticals LP
Nov 13, 2025
Consulting Fee
DATROWAY · Oncology
$3,280
Nov 13, 2025AstraZeneca UK Limited
Nov 13, 2025
Consulting Fee$2,460
Nov 12, 2025Merck Sharp & Dohme LLC
Nov 12, 2025
Consulting Fee$1,280
Nov 11, 2025AstraZeneca Pharmaceuticals LP
Nov 11, 2025
Consulting Fee
DATROWAY · Oncology
$3,690
Nov 6, 2025Gilead Sciences, Inc.
Nov 6, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4267674;VEM US;11024743
$1,240
Oct 23, 2025Gilead Sciences, Inc.
Oct 23, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4253564;VEM US;11024743
$1,820
Oct 20, 2025AstraZeneca UK Limited
Oct 20, 2025
Consulting Fee
DATROWAY · Oncology
Company’s descriptionResearch Related Service
$685
Oct 18, 2025Gilead Sciences, Inc.
Oct 18, 2025
Travel and Lodging
Trodelvy · ONC · travel to Foster City, CA · in-kind
Company’s description;4253436;VEM US;11024743
$634
Oct 9, 2025Stemline Therapeutics Inc.
Oct 9, 2025
Consulting Fee
Orserdu · Oncology
$4,680
Oct 8, 2025BioNTech SE
Oct 8, 2025
Consulting Fee$6,750
Oct 8, 2025BioNTech SE
Oct 8, 2025
Consulting Fee$4,725
Sep 25, 2025AstraZeneca Pharmaceuticals LP
Sep 25, 2025
Consulting Fee
ENHERTU · Oncology
$3,280
Sep 25, 2025Gilead Sciences, Inc.
Sep 25, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4289905;GTF;11024743
$725
Aug 28, 2025Gilead Sciences, Inc.
Aug 28, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4252159;GTF;11024743
$1,450
Aug 28, 2025Gilead Sciences, Inc.
Aug 28, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4252167;GTF;11024743
$725
Aug 19, 2025Gilead Sciences, Inc.
Aug 19, 2025
Consulting Fee
Trodelvy · ONC
Company’s description;4289907;GTF;11024743
$725
Aug 13, 2025Merck Sharp & Dohme LLC
Aug 13, 2025
Consulting Fee$1,280
Jul 28, 2025Genentech, Inc.
Jul 28, 2025
Consulting Fee$1,900
Jul 25, 2025Stemline Therapeutics Inc.
Jul 25, 2025
Consulting Fee
Orserdu · Oncology
$780
Jul 25, 2025Stemline Therapeutics Inc.
Jul 25, 2025
Consulting Fee
Orserdu · Oncology
$390
Jul 16, 2025Gilead Sciences, Inc.
Jul 16, 2025
Consulting Fee
Company’s description;4275678;VEM US;11024743
$1,450
Jun 25, 2025AstraZeneca Pharmaceuticals LP
Jun 25, 2025
Consulting Fee$820
Jun 11, 2025Genentech, Inc.
Jun 11, 2025
Consulting Fee$858
May 30, 2025Gilead Sciences, Inc.
May 30, 2025
Travel and Lodging
travel to Chicago, IL
Company’s description;4275670;VEM US;11024743
$18.60
May 23, 2025Stemline Therapeutics Inc.
May 23, 2025
Consulting Fee
Orserdu · Oncology
$780
May 15, 2025Genentech, Inc.
May 15, 2025
Consulting Fee$1,710
May 2, 2025AstraZeneca Pharmaceuticals LP
May 2, 2025
Consulting Fee
DATROWAY · Oncology
Company’s descriptionResearch Related Service
$4,110
Apr 11, 2025AstraZeneca Pharmaceuticals LP
Apr 11, 2025
Consulting Fee
DATROWAY · Oncology
$1,370
Feb 10, 2025Genentech, Inc.
Feb 10, 2025
Consulting Fee$1,710
Jan 22, 2025Genentech, Inc.
Jan 22, 2025
Consulting Fee$1,155

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $656,495 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
    AstraZeneca Pharmaceuticals LP
  • A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
    AstraZeneca Pharmaceuticals LP
  • BNT327-02
    BioNTech SE
  • An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
    Astellas Pharma Global Development
  • A phase iii multicenter randomized open label study comparing atezolizumab anti pd L1 antibody
    Hoffmann-la Roche Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated February 24, 2015), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1730285990. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.